Human sodium/iodide symporter-mediated radioiodine gene therapy enhances the killing activities of CTLs in a mouse tumor model

Molecular Cancer Therapeutics

Volumn 9, Issue 1, 2010, Pages 126-133

  Jeon, Yong Hyun ^a,b,c   Choi, Yun ^b   Kim, Chul Woo ^b   Kim, Young Hwa ^a,b   Youn, Hyewon ^a,b   Lee, Jaetae ^b   Chung, June Key ^a,b  

^a Seoul National University   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Kyungpook National University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; CD86 ANTIGEN; CELL SURFACE MARKER; COTRANSPORTER; FAS LIGAND; GAMMA INTERFERON; GLYCOPROTEIN P 15095; IODINE 125; IODINE 131; LACTATE DEHYDROGENASE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PERTECHNETIC ACID TC 99M; SODIUM IODIDE SYMPORTER; THYROXINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER GENE THERAPY; CANCER INHIBITION; CD8+ T LYMPHOCYTE; CELL SURVIVAL; CLONOGENIC ASSAY; COLON ADENOCARCINOMA; COLON CANCER; CONTROLLED STUDY; DENDRITIC CELL; DOSE RESPONSE; DRUG CYTOTOXICITY; FEMALE; GENE; GENE EXPRESSION; HUMAN; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RADIOISOTOPE THERAPY; SODIUM IODIDE SYMPORTER GENE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL DESTRUCTION; TUMOR IMMUNITY;

ANIMALS; ANTIGENS, CD11C; ANTIGENS, CD86; CELL LINE, TUMOR; CELL MEMBRANE; CELL PROLIFERATION; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; GENE THERAPY; HUMANS; INTERFERON-GAMMA; IODINE RADIOISOTOPES; LYMPHOCYTE COUNT; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; NEOPLASMS; PHENOTYPE; SYMPORTERS; T-LYMPHOCYTES, CYTOTOXIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 73949090478     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-0540     Document Type: Article

References (25)

1. Gurunathan S, Klinman DM, Seder RA. DNA vaccines: immunology, application, and optimization*. Annu Rev Immunol 2000;18:927-74.
2. Rosenberg SA, Yang JC, Sherry RM, et al. Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen. Hum Gene Ther 2003;14: 709-14.
3. Ferrone S, Marincola FM. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today 1995;16:487-94.
4. Smyth MJ, Godfrey DI, Trapani JA. A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol 2001;2:293-9.
5. Dudley ME, Rosenberg SA. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev 2003;3:666-75.
6. Watters D. Molecular mechanisms of ionizing radiation-induced apoptosis. Immunol Cell Biol 1999;77:263-71.
7. Klein B, Loven D, Lurie H, et al. The effect of irradiation on expression of HLA class I antigens in human brain tumors in culture. J Neurosurg 1994;80:1074-7.
8. Chakraborty M, Abrams SI, Camphausen K, et al. Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J Immunol 2003;170:6338-47.
9. Chakraborty M, Wansley EK, Carrasquillo JA, et al. The use of chelated radionuclide (samarium-153-ethylenediaminetetramethylenephosphonate) to modulate phenotype of tumor cells and enhance T cell-mediated killing. Clin Cancer Res 2008;14:4241-9.
10. Chung JK. Sodium/iodide symporter: its role in nuclear medicine. J Nucl Med 2002;43:1188-200.
11. De La Vieja A, Dohan O, Levy O, Carrasco N. Molecular analysis of the sodium/iodide symporter: impact on thyroid and extrathyroid pathophysiology. Physiol Rev 2000;80:1083-105.
12. Cho JY. A transporter gene (sodium/iodide symporter) for dual purposes in gene therapy: imaging and therapy. Curr Gene Ther 2002;2: 393-402.
13. Chen L, Altmann A, Mier W, et al. Radioiodine therapy of hepatoma using targeted transfer of the human sodium/iodide symporter gene. J Nucl Med 2006;47:854-62.
14. Mandell RB, Mandell LZ, Link CJ, Jr. Radioisotope concentrator gene therapy using the sodium/iodide symporter gene. Cancer Res 1999;59:661-8.
15. Jeon YH, Choi Y, Kim HJ, et al. Human sodium/iodide symporter gene adjunctive radiotherapy to enhance the preventive effect of hMUC1 DNA vaccine. Int J Cancer 2007;121:1593-9.
16. Jeon YH, Choi Y, Yoon SO, Kim CW, Chung JK. Synergistic tumoricidal effect of combined hMUC1 vaccination and hNIS radioiodine gene therapy. Mol Cancer Ther 2008;7:2252-60.
17. Kim HJ, Jeon YH, Kang JH, et al. In vivo long-term imaging and radioiodine therapy by sodium-iodide symporter gene expression using a lentiviral system containing ubiquitin C promoter. Cancer Biol Ther 2007;6.
18. Gilboa E. How tumors escape immune destruction and what we can do about it. Cancer Immunol Immunother 1999;48:382-5.
19. Garcia-Lora A, Algarra I, Garrido F. MHC class I antigens, immune surveillance, and tumor immune escape. J Cell Physiol 2003;195: 346-55.
20. Garcia-Lora A, Algarra I, Collado A, Garrido F. Tumour immunology, vaccination and escape strategies. Eur J Immunogenet 2003;30: 177-83.
21. Bubenik J. Tumour MHC class I downregulation and immunotherapy (review). Oncol Rep 2003;10:2005-8.
22. Kojima H, Shinohara N, Hanaoka S, et al. Two distinct pathways of specific killing revealed by perforin mutant cytotoxic T lymphocytes. Immunity 1994;1:357-64.
23. Garnett CT, Palena C, Chakraborty M, Tsang KY, Schlom J, Hodge JW. Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res 2004;64:7985-94.
24. Demaria S, Bhardwaj N, McBride WH, Formenti SC. Combining radiotherapy and immunotherapy: a revived partnership. Int J Radiat Oncol Biol Phys 2005;63:655-66.
25. Gulley JL, Arlen PM, Bastian A, et al. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res 2005;11:3353-62.